中 | EN

Investors

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF THE ITERATIVE-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE
2024-11-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
2024-11-04
VOLUNTARY ANNOUNCEMENT - 13-VALENT PNEUMONIA CONJUGATE VACCINE PHASE III CLINICAL TRIALS COMPLETED, PRODUCTION LICENSE OBTAINED AND APPLICATION FOR DRUG MARKETING REGISTRATION DULY SUBMITTED
2024-10-31
VOLUNTARY ANNOUNCEMENT - MRNA RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
2024-10-30
VOLUNTARY ANNOUNCEMENT - UNBLINDING OF DATA FROM PHASE III CLINICAL TRIAL OF ITERATIVE SERUM-FREE RABIES VACCINE: PRE-DEFINED CLINICAL OBJECTIVES MET WITH GOOD IMMUNOGENICITY AND SAFETY
2024-10-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
2024-10-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
2024-09-03
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
2024-08-29
RE-DESIGNATION OF DIRECTORS
2024-08-29
VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
2024-08-29
VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED (43K
2024-08-29
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR MRNA RSV AND MRNA SHINGLES/HERPES ZOSTER VACCINES OF AIM VACCINE SUBMITTED TO FDA
2024-08-29
NOTICE OF BOARD MEETING
2024-08-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
2024-08-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
2024-07-02
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR TWO MRNA VACCINES OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND SHINGLES/HERPES ZOSTER OF AIM VACCINE SUBMITTED
2024-06-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
2024-06-04
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2024
2024-05-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-05-07
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2024-05-07
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2024
2024-04-25
NOTICE OF 2023 ANNUAL GENERAL MEETING
2024-04-25
CIRCULAR OF 2023 ANNUAL GENERAL MEETING
2024-04-25
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-04-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-04-03
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2024-04-03
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE SUBMIT
2024-03-28
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
2024-03-28
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
2024-03-28
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR NOVEL-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE SUBMITTED
2024-03-26
NOTICE OF BOARD MEETING
2024-03-15
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED
2024-03-04
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE
2024-03-04
PROFIT WARNING
2024-03-04
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
2024-03-04
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE PNEUMONIA VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
2024-03-04
VOLUNTARY ANNOUNCEMENT - EXPECTED COMPLETION OF APPLICATION FOR MARKETING OF 13-VALENT PNEUMONIA CONJUGATE VACCINE, ITERATIVE SERUM-FREE RABIES VACCINE AND 23-VALENT PNEUMONIA POLYSACCHARIDE VACCINE IN 2024
2024-03-04
VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR MARKETING REGISTRATION FOR 13-VALENT PNEUMONIA CONJUGATE VACCINE SUBMITTED
2024-03-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
2024-03-01
(1) POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 29, 2024; (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) APPOINTMENTS OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD HAVING BECOME EFFECTIVE
2024-02-29
(1) Notification Letter to Non-registered Shareholder and (2) Updated Arrangement of Electronic Dissemination of Corporate Communications
2024-02-08
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 29, 2024
2024-02-08
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
2024-02-08
NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
2024-02-08
(1) ELECTION OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
2024-02-08
CLOSURE OF REGISTER OF MEMBERS
2024-02-07
Arrangement of Electronic Dissemination of Corporate Communications
2024-02-01
New Arrangements on Dissemination of Corporate Communications
2024-02-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-02-01
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-01-10
VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2024-01-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-01-02
VOLUNTARY ANNOUNCEMENT - ANNOUNCEMENT ON THE 2023 CORPORATE DAY EVENT
2023-12-27
VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2023-12-12
VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2023-12-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2023-12-04
VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE MSCI GLOBAL SMALL CAP INDEX
2023-12-01
VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2023-11-30
Articles of Association
2023-11-28
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2023-11-28
(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING, THE DOMESTIC SHARE CLASS MEETING AND THE H SHARE CLASS MEETING HELD ON NOVEMBER 28, 2023; (2) ELECTION OF THE BOARD OF DIRECTORS IN THE SECOND SESSION; (3) ELECTION OF THE BOARD OF SUPERVISORS IN THE SECOND SESSION; (4) APPOINTMENT OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS IN THE SECOND SESSION; (5) CHANGE OF REGISTERED OFFICE; AND (6) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
2023-11-28
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2023-11-21
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
2023-11-17
FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2023 THIRD H SHARE CLASS MEETING TO BE HELD ON NOVEMBER 28, 2023
2023-11-09
FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON NOVEMBER 28, 2023
2023-11-09
CIRCULAR FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
2023-11-09
NOTICE OF THE H SHARE CLASS MEETING
2023-11-09
NOTICE OF THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
2023-11-09
(1) PROPOSED RE-ELECTION OF DIRECTORS IN THE SECOND SESSION; (2) PROPOSED RE-ELECTION OF SHAREHOLDER REPRESENTATIVE SUPERVISORS IN THE SECOND SESSION; (3) PROPOSED CHANGE OF REGISTERED OFFICE; AND (4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
2023-11-09
CLOSURE OF REGISTER OF MEMBERS
2023-11-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
2023-11-03
CHANGE IN USE OF IPO PROCEEDS
2023-10-23
VOLUNTARY ANNOUNCEMENT - INTENTION TO REPURCHASE SHARES ON THE MARKET
2023-10-23
VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR A SHARE LISTING TUTORING HAS BEEN FORMALLY ACCEPTED BY THE REGULATORY AUTHORITY
2023-10-17
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IS NEAR COMPLETION AND STATISTICAL UNBLINDING WILL COMMENCE SOON
2023-10-17
VOLUNTARY ANNOUNCEMENT - SIGNING OF A SHARE LISTING TUTORING AGREEMENT AND FILING OF REGISTRATION APPLICATION FOR A SHARE LISTING TUTORING
2023-10-12
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS
2023-10-09
INITIATION OF A SHARE LISTING PLAN
2023-10-08
VOLUNTARY ANNOUNCEMENT - COMPLETION OF FULL COURSE OF VACCINATION IN SUBJECTS OF PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
2023-10-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
2023-10-06
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SERUM-FREE RABIES VACCINE ACHIEVED SATISFACTORY PHASE RESULTS
2023-09-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
2023-09-05
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
2023-09-05
VOLUNTARY ANNOUNCEMENT - THE APPROVAL FOR THE ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES FROM THE CSRC
2023-08-30
VOLUNTARY ANNOUNCEMENT - INITIATION OF RANDOMIZED, BLINDED AND COMPARABLE VACCINE-CONTROLLED PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
2023-08-29
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
2023-08-29
NOTICE OF BOARD MEETING
2023-08-17
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
2023-08-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
2023-07-03
VOLUNTARY ANNOUNCEMENT - BIVALENT mRNA VACCINE AGAINST COVID-19 VARIANTS DELTA AND OMICRON BA.5 OBTAINED CLINICAL TRIAL APPROVALS FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2023-06-29
VOLUNTARY ANNOUNCEMENT - APPLICATION ACCEPTED FOR CLINICAL TRIAL OF HUMAN RABIES mRNA VACCINE AGAINST RABIES VIRUS
2023-06-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023
2023-06-01
VOLUNTARY ANNOUNCEMENT MAJOR RESULTS OF A DOMESTIC STUDY ON PROTECTIVE EFFICACY OF COVID-19 VARIANT OMICRON BA.5 mRNA VACCINE LVRNA012
2023-06-01
© 2022 艾美疫苗股份有限公司 All rights reserved. 京ICP备20027818号-1 京公网安备11010502045274号